GeneToBe — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

GeneToBe is a private, preclinical-stage biotech developing transformative gene therapies for genetically-defined diseases. The company leverages a dual-technology platform centered on a proprietary, high-fidelity CRISPR-Cas9 system (MiCas9) and a liver-selective siRNA platform for gene silencing. Its pipeline targets significant unmet needs in cystic fibrosis, Usher syndrome, and liver diseases like MASH, positioning it in high-value therapeutic areas. Founded in 2016 as a University of Michigan spinout, the company is backed by private angel investors and led by a team with strong scientific and clinical development expertise.

Cystic FibrosisUsher SyndromeMetabolic Dysfunction-associated SteatohepatitisAlcoholic Liver Disease

Technology Platform

Dual-platform integrating 1) a liver-selective siRNA gene silencing platform with 'bias targeting' capability, and 2) a proprietary, high-fidelity CRISPR-Cas9 gene editing system (MiCas9) enhanced by Brex27 to improve Homology Directed Repair efficiency and specificity. Supported by proprietary genetically-modified rabbit disease models.

Opportunities

The company is targeting multi-billion dollar markets in MASH and Cystic Fibrosis, where transformative, one-time genetic medicines could command premium pricing.

Its platform-agnostic technology could be expanded to other genetically-defined diseases, creating significant optionality.

Success in its rare disease program (Usher Syndrome) could offer accelerated regulatory pathways and strong patient advocacy support.

Risk Factors

All assets are in preclinical stages, carrying high technical and translational risk.

The company's reliance on angel funding may be insufficient for the capital-intensive path to the clinic, creating execution risk.

It faces intense competition in both the gene editing and MASH therapeutic landscapes from larger, better-funded entities.

Competitive Landscape

In gene editing for Cystic Fibrosis and Usher Syndrome, GeneToBe competes with other CRISPR-focused biotechs (e.g., Editas Medicine, Intellia Therapeutics) and gene therapy companies. In MASH, it faces competition from large pharma and biotech firms developing small molecules, antibodies, and other modalities, though its siRNA approach is less crowded. Its MiCas9 platform must differentiate against established and next-generation editing tools from leaders like CRISPR Therapeutics and Beam Therapeutics.

More companies in CRISPR / Gene Editing →More companies in United States →